Bevacizumab combined with cisplatin in the treatment of malignant pleural effusion in patients with NSCLC

Abstract

Objective To investigate the value of bevacizumab combined with cisplatin in the treatment of malignant pleural effusion in patients with non-small cell lung cancer (NSCLC). Methods 86 patients with NSCIC and malignant tumor effusion admitted to our hospital from June, 2017 to December, 2018 were selected and divided into a control group (n=43, cisplatin intrapleural perfusion) and an observation group (n=43, bevacizumab combined with cisplatin) according to the envelope method. The chemotherapy effects of the two groups were compared. Results The effective rate of the observation group was higher than that of the control group (79.07% vs. 46.51%). In the first, second, and third treatment cycles, the expressions of VEGF were lower in the observation group than in the control group [ (91.36±25.45) pg/ml vs. (185.35±26.84) pg/ml, (49.02±12.71)pg/ml vs. (125.71±13.02) pg/ml, and (25.96±6.62) pg/ml vs. (68.42±8.91) pg/ml; all P 0.05). After the treatment, the expressions of CEA and SCCAg was lower and the quality of life was higher in the observation group than in the control group [(21.61±3.25) ng/ml vs. (31.75±3.31) ng/ml, (20.35±3.17) ng/ml vs. (27.65±3.24) ng/ml, and (96.24±10.15) vs. (76.25±10.08); all P 0.05). Conclusion Bevacizumab combined with cisplatin can effectively control malignant pleural effusion in patients with non-small cell lung cancer and has high clinical value. Key words: Bevacizumab; Cisplatin; Non-small cell lung cancer; Malignant pleural effusion